A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ABP-671

Inclusion Criteria

• •Subjects must be medically documented as healthy and acceptable at screening.
• •Subjects must have serum uric acid level at screening ≥ 7.0 mg/dL for men, ≥ 6.0 mg/dL for women.
• •Subjects must have a Body Mass Index (BMI) between 18.0 and 34.0 kg/m2 (inclusive).
• •Subjects must have a body weight of 50 kg or higher.
• •The subject agrees to abstain from alcohol consumption for 48 hours prior to dosing, for the duration of the in-house study period, and for 48 hours prior to each in-clinic follow up visit.
• •The subject is a nonsmoker.
• •Women must be non-pregnant and non-lactating, and either surgically sterile or postmenopausal for ≥ 12 months.
• •Men must be surgically sterile, abstinent or if engaged in sexual relations with a female partner of child-bearing potential, the participant must be using a condom with spermicide from Screening and for a period of 30 days after the last dose of Study Drug. The Investigator will assess the adequacy of methods of contraception on a case-by-case basis.
• •Subjects must have a complete blood count (CBC) and platelet count within the normal range or considered not clinically significant by the principal investigator.
• •Other than elevated serum uric acid, subjects must have normal blood chemistry or results considered not clinically significant by the investigator.
• •Subjects must have a normal urinalysis or results considered not clinically significant by the investigator including a normal protein/creatinine ratio per local lab reference ranges (≤ 200 mg/g) and a urine creatinine result that does not exceed 300 mg/dL. Any out of range values may be repeated per Investigator discretion.
• •Subjects must have a normal ECG or results considered not clinically significant by the principal investigator.
• •Subjects must be able to comply with the study and follow-up procedures.
• •Subjects are able to understand the study procedures and risks involved and must provide signed informed consent to participate in the study.